Hepatitis B Testing

Hepatitis B testing supports diagnosis, treatment decisions, prevention of transmission, and monitoring of people with current or past infection. Core testing commonly includes hepatitis B surface antigen (HBsAg), antibodies to hepatitis B surface antigen and core antigen, and, when clinically indicated, hepatitis B e antigen and HBV DNA testing. The public-health value of testing is closely linked to vaccination, linkage to care, safe blood services, and prevention of mother-to-child transmission. WHO identifies chronic hepatitis B as a major global health concern and recommends testing approaches that expand access among people with relevant exposure, clinical, or geographic risk.

The testing landscape is moving from facility-based diagnosis alone toward integrated services in primary care, antenatal care, sexual-health services, harm-reduction programs, prisons, migrant-health programs, and community settings. Simplified testing pathways, reflex or streamlined laboratory workflows, dried-blood-spot approaches, and validated point-of-care tools can reduce the number of visits required before a person receives a result or is linked to care. These shifts require quality assurance, clear interpretation of serological patterns, confirmatory pathways, appropriate biosafety, and reliable referral systems. Elimination efforts also increasingly emphasize testing people who are undiagnosed, rather than focusing only on patients who already present with liver disease.

Artificial intelligence can support hepatitis B testing by prioritizing records for follow-up, identifying missed testing opportunities in electronic health data, assisting laboratory quality-control review, and improving interpretation support when serological results are complex. Predictive tools may also help identify people who would benefit from confirmatory testing or linkage to specialist care. However, these applications require representative training data, external validation, privacy safeguards, explainability, and clinician oversight. AI should augment-not replace-validated assays, laboratory professionals, and public-health judgment, particularly where false negatives could delay treatment or prevention of transmission.

In North America, priorities include testing in underserved communities, migrants from higher-prevalence settings, people with HIV or hepatitis C, and pregnant patients, alongside stronger linkage to care. Latin America benefits from integrating hepatitis B testing with vaccination, maternal services, blood safety, and primary care. Europe must address uneven diagnosis, migration-related access barriers, and testing among people who inject drugs and other higher-risk populations. The Middle East requires context-sensitive services for refugees, migrants, and populations affected by disrupted health systems. Africa faces the need to expand affordable diagnostics, antenatal screening, vaccination at birth, and referral capacity. Asia-Pacific contains substantial diversity, with continued emphasis on birth-dose vaccination, household and sexual-contact testing, rural access, and chronic-disease monitoring.

ASEAN members can strengthen cross-border continuity of testing, maternal services, and vaccination while adapting delivery to urban, rural, and migrant populations. BRICS countries encompass varied epidemiological and health-system conditions, making shared laboratory standards, affordable procurement, and workforce development particularly relevant. The European Union can benefit from interoperable surveillance, consistent testing guidance, and improved access for mobile and marginalized populations. G7 members can support high-quality screening, equitable domestic access, and international technical cooperation. GCC countries need testing pathways that serve citizens, migrant workers, and pregnant populations within diverse regulatory systems. NATO members can reinforce testing continuity during emergencies, deployments, displacement, and health-system disruption, while maintaining strong laboratory governance.

Australia should continue targeted testing for priority populations and strengthen culturally safe services for Aboriginal and Torres Strait Islander communities. Brazil and Mexico can integrate testing with primary care, maternal health, vaccination, and community outreach. Canada, the United States, the United Kingdom, France, Germany, Italy, and Spain can improve diagnosis among migrants, people with limited healthcare access, and other clinically or epidemiologically indicated groups while ensuring referral completion. China and India face the importance of broadening accessible testing and linkage across urban, rural, and regional health systems. Japan and South Korea can reinforce testing among older adults, household contacts, and people with relevant clinical histories, alongside long-term monitoring. Russia can benefit from consistent testing quality, prevention services, and continuity across geographically dispersed populations. Across all countries, national guidance should clearly define who to test, how to interpret results, and how to connect positive cases and exposed contacts to care or prevention.

Leaders should design testing programs around the complete pathway from eligibility assessment to result delivery, confirmatory testing, clinical evaluation, vaccination of susceptible contacts, and long-term follow-up. Priority actions include using validated assays, expanding decentralized and self-collection options where permitted, embedding testing in antenatal and primary-care workflows, and monitoring turnaround time and linkage completion rather than test volume alone. Organizations should segment services by local risk and access barriers, train staff in result interpretation, protect patient confidentiality, and establish quality indicators for invalid results, repeat testing, referral loss, and equity. AI-enabled tools should be introduced through controlled pilots with bias testing, audit trails, human review, and clearly defined accountability.

This executive summary uses a structured synthesis of authoritative public-health guidance, surveillance materials, peer-reviewed evidence, laboratory standards, and documented testing practices. The assessment compares diagnostic roles for serology, nucleic-acid testing, and point-of-care or specimen-collection approaches; examines access, prevention, and linkage considerations across the specified regions, groups, and countries; and evaluates emerging digital and AI applications against requirements for validation, privacy, and clinical oversight. Findings are framed qualitatively and do not represent market estimates, forecasts, market shares, or financial projections. Country and regional observations should be interpreted alongside current national guidance, local epidemiology, regulatory requirements, and available laboratory capacity.

Hepatitis B testing has its greatest impact when it is accessible, accurately interpreted, connected to vaccination and prevention, and followed by timely clinical evaluation. Regional and country differences make a single delivery model unsuitable, but common priorities are clear: test people who are most likely to benefit, reduce logistical barriers, protect quality, and measure whether patients reach appropriate care. Artificial intelligence may improve targeting and operational performance, yet trustworthy implementation depends on validated diagnostics, skilled professionals, transparent governance, and equity-focused evaluation. Industry leaders that build integrated, patient-centered pathways can help convert testing from an isolated laboratory event into a practical instrument for reducing transmission and liver-related harm.